Canterbury DHB

Context

Supportive Measures

The following are recommended:

The following are recommended for fludarabine-based treatment:

In This Section

Vaccines

Antiemetics

Blood products

Splenectomy

Vaccines

Patients with CLL should receive annual influenza vaccinations. In addition pneumoccocal vaccination is also advised. Although antibody formation by CLL patients may be sub-optimal, pneumonia is a common cause of death in this disease.

Antiemetics

See Nausea and Vomiting.

Blood products

Blood and platelet transfusions will be given at the discretion of the treating physician. Patients treated with fludarabine or fludarabine plus cyclophosphamide must receive irradiated blood products to prevent the rare occurrence of transfusion associated graft versus host disease. This should continue for at least 6 months after the end of the fludarabine therapy.

Splenectomy

This may be indicated in non-responding patients who remain with a markedly enlarged spleen after an adequate trial of primary therapy. For further information, see Prevention of Infection Pre-splenectomy and in Splenic Atrophy in the Infection including Prophylaxis section.

About this Canterbury DHB document (5530):

Document Owner:

Andrew Butler (see Who's Who)

Issue Date:

September 2018

Next Review:

September 2021

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 5530